| Literature DB >> 30299482 |
M Candiani1, J Ottolina1, E Posadzka2, S Ferrari1, L M Castellano1, I Tandoi1, L Pagliardini3, A Nocun4, R Jach2.
Abstract
STUDY QUESTION: Does CO2 laser vaporization offer better results in treating endometrioma in terms of ovarian reserve preservation compared to traditional cystectomy? SUMMARY ANSWER: Assessing both antral follicle count (AFC) and serum anti-Müllerian hormone (AMH) levels as measures of ovarian reserve, the results suggest that CO2 technology may be an alternative treatment for endometrioma, causing minimal damage to adjacent healthy ovarian tissue. WHAT IS KNOWN ALREADY: Excisional surgery has been questioned as an ideal surgical approach for endometriomas because it is associated with potential reduction of ovarian reserve. Recently, vaporization with CO2 laser in-line-of-sight, according to the 'three-step procedure', has been proposed as the best method to preserve ovarian function. However, no randomized controlled trials have been conducted to compare cystectomy and 'one-step' CO2 fiber laser vaporization (without GnRH agonist therapy) with respect to the ovarian reserve. STUDY DESIGN, SIZE, DURATION: A multicentre randomized clinical trial including 60 patients was performed between July 2017 and February 2018. Computerized randomization was conducted to allocate them in a proportion of 1:1 either to Group 1 (laparoscopic stripping: cystectomy) or Group 2 (CO2 laser vaporization). Patients in Group 1 underwent a standardized laparoscopic stripping technique; patients in Group 2 underwent drainage of the cyst content, biopsy and vaporization of the internal wall with a CO2 fiber laser. Patients underwent pelvic ultrasound examination to determine the AFC and blood sampling to determine AMH levels before surgery and at 1- and 3-month follow-up. PARTICIPANTS/MATERIALS, SETTING,Entities:
Mesh:
Year: 2018 PMID: 30299482 PMCID: PMC6238368 DOI: 10.1093/humrep/dey305
Source DB: PubMed Journal: Hum Reprod ISSN: 0268-1161 Impact factor: 6.918
Figure 1Flow chart of participants from recruitment to follow-up in a study of ovarian reserve after cystectomy versus CO2 laser vaporization in the treatment of ovarian endometrioma.
Baseline clinical characteristics and ultrasonographic findings of the two groups of patients with ovarian endometrioma.
| Characteristics | Cystectomy Group 1 ( | CO2 laser vaporization Group 2 ( |
|---|---|---|
| Age (years) | 30.3 ± 5.2 | 32.1 ± 4.8 |
| Indications for surgery | ||
| Dysmenorrhea | 12 (40) | 13 (43.3) |
| Chronic pelvic pain | 18 (60) | 16 (53.3) |
| Dyspareunia | 5 (16.7) | 4 (13.3) |
| Infertility | 10 (33.3) | 11 (36.7) |
| Pregnancy desire | 19 (63.3) | 17 (56.7) |
| BMI (kg/m2) | 21.8 ± 2.3 | 20.7 ± 2.9 |
| Diameter of the cyst | 4.9 ± 1.5 | 4.7 ± 1.4 |
| Bilateral endometrioma | 3 (10) | 6 (20) |
| Endometriomas in right ovary | 15 (50) | 15 (50) |
| Endometriomas in left ovary | 18 (60) | 21 (70) |
Values are mean±SD or n (%).
Surgical characteristics and follow-up of the two groups of patients.
| Characteristics | Cystectomy Group 1 ( | CO2 laser vaporization Group 2 ( | |
|---|---|---|---|
| Operative time (min) | 56.5 ± 22.3 | 54.3 ± 21 | 0.66 |
| Operative time for endometrioma (min) | 26.8 ± 8.2 | 23.2 ± 7.9 | 0.09 |
| Hospital stay (days) | 2.3 ± 0.6 | 2.4 ± 0.6 | 0.75 |
| Follow-up (months) | 7.8 ± 1.5 | 8.1 ± 1.4 | 0.8 |
| Postoperative improvement of dysmenorrhea | 11/12 (91.7) | 12/13 (92.3) | 0.6 |
| Postoperative improvement of chronic pelvic pain | 15/18 (83.3) | 13/16 (81.3) | 0.9 |
| Postoperative improvement of dyspareunia | 2/5 (40) | 2/4 (50) | 0.65 |
Values are mean±SD or n (%). Data were analyzed using Chi square test, Fisher’s exact test, Student’s t-test and Mann–Whitney test according to variables type and data distribution.
Comparison of the sonographic and serum indicators of ovarian reserve in patients before and 3 months after surgery.
| Variable | Cystectomy ( | Group 1 Month 3 | 95% CI | CO2 laser vaporization ( | Group 2 Month 3 | 95% CI | Adj. | ||
|---|---|---|---|---|---|---|---|---|---|
| AFC | 4.1 ± 2.2 | 6.3 ± 3.5 | 0.9–4 | 0.06 | 3.6 ± 1.9 | 8.6 ± 4.2 | 2.8–7.1 | ||
| Serum AMH (ng/mL) | 2.6 ± 1.4 | 1.8 ± 0.8 | −1.3 – −0.2 | 0.012 | 2.3 ± 1.1 | 1.9 ± 0.9 | −1 – −0.2 | 0.09 |
*Intra-group Student’s t-test.
**Linear regression analysis adjusted for patients’ age.
Values are mean ± SD.
AFC = antral follicle count (operated ovary).
AMH = anti-Müllerian hormone.